ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

Drug Development Effort Criticized

April 18, 1975

UC Breast Cancer ProgramTo Award $20 Million In Grants

December 16, 1994

IG Report Clears Shubik Of Conflict Of Interest Change

October 6, 1978

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years.

February 20, 2004

Study Finds 4-20% Of Those With HTLV-3 Develop AIDs Within 32 Months Or Less

August 2, 1985